← Eichor
Condition: Newly Diagnosed Acute Myeloid Leukemia With High Risk Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Newly Diagnosed Acute Myeloid Leukemia With High Risk

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

HVA vs IA/DA or VA in the Treatment of ND HR-AML
Phase 3 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06810791ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05010122Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Phase 2 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06483906Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory A
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04047641High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML
Phase 1 · 1 location(s) · Kittika Poonsombudlert · NCT07177079A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06928376Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06394011Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Phase 1 · 1 location(s) · Montefiore Medical Center · NCT05342584Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myelo
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03214562Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07259707Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia
Phase 2 · 222 location(s) · National Cancer Institute (NCI) · NCT05554406
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.